HCmed Signs a Global Development Agreement with CSL Behring to develop a combination product
On May 04, 2021, HCmed has announced the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring's plasma-derived immunoglobulin administered via HCmed’s new generation vibrating-mesh nebulising device (CSL787).
As per the deal between the two companies, CSL Behring will have complete responsibility for developing and commercialising the combination product. HCmed leads the development of the customised nebulising device specifically optimised for CSL Behring’s formulation. Payment will be given to HCme...
